Winterlight
Acquired3 known investors
Winterlight Labs develops a tablet-based, speech analysis platform that extracts digital biomarkers from short speech samples to detect and monitor cognitive impairment linked to dementia and mental illness. It serves life science research, clinical trials, and senior care settings, offering assessment tools and an API for speech-based analysis.
Also known as Winterlight Labs
Investors · 3
Company profile
researched Aug 2026Winterlight Labs develops a tablet-based cognitive assessment that analyzes speech alone to detect cognitive impairment associated with dementia and mental illness. The assessment is positioned as fast, objective and stress-free relative to existing neurological assessments, which the company describes as slow, subjective and difficult to administer remotely. Its technology extracts speech-based digital biomarkers from short snippets of speech, and the assessment is applied in life science research, senior care and clinical settings.
The company offers three main lines of use: vocal biomarkers for clinical trials, where it supports life science partners with site onboarding, data collection, speech analysis and results interpretation; ratings quality assurance, which automates the review of clinical assessment administration and scoring in trials through fast auditing and analysis; and a speech analysis API that provides clinically validated speech-based biomarkers, usable either on previously collected speech data or integrated into an application or device that continuously collects speech. Winterlight also recruits participants of all ages for its own research studies on speech patterns to improve disease detection and monitoring tools.
Business model
Winterlight supplies its speech-based assessment, ratings quality assurance service and speech analysis API to life science partners running clinical trials, as well as to senior care and clinical settings, supporting partners across trial site onboarding, data collection, analysis and interpretation.
Traction
The Winterlight Assessment is used in a dozen clinical trials to track changes and identify treatment responses, and the company reports five of the top ten life sciences companies as users. It has run collaborations with Genentech on Alzheimer's disease speech measures and with Alzheimer Center Amsterdam on preclinical Alzheimer's research.
Latest developments
In January 2023, Cambridge Cognition announced the acquisition of Winterlight, positioning the combined organization in voice and digital biomarkers for clinical trials. In October 2022, Winterlight and Genentech announced data showing the sensitivity of speech-based digital measures in detecting longitudinal change in Alzheimer's disease; in March 2022, Winterlight began a funded study with Alzheimer Center Amsterdam on decentralized assessments in preclinical Alzheimer's disease and presented research at ADPD 2022 linking speech characteristics to cerebral tau accumulation measured by tau PET imaging.
▸Full profile — market position, technology, go-to-market, history
Market position
The company states it is trusted by five of the top ten life sciences companies to measure disease progression and response to therapy, and that its assessment is used in about a dozen clinical trials.
Winterlight contrasts its approach with conventional neurological assessments, emphasizing objective, quick and remotely deliverable measurement derived from short speech samples rather than clinician-administered subjective scoring.
Technology
A tablet-based assessment that extracts clinically validated speech-based digital biomarkers from short snippets of speech, delivered also through an API that can analyze previously collected speech data or integrate with applications and devices that continuously collect speech.
Go-to-market
Life science and pharmaceutical companies running clinical trials, academic and clinical researchers, clinicians, and senior care providers.
History
Winterlight developed a speech-based cognitive assessment used in life science research and clinical trials, conducted collaborative research with Genentech and Alzheimer Center Amsterdam during 2022, and was acquired by Cambridge Cognition in January 2023.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 4
launches, deals, and filingsCambridge Cognition announced the acquisition of Winterlight, combining efforts in voice and digital biomarkers for clinical trials.
Winterlight Labs and Genentech announced data demonstrating the sensitivity of speech-based digital measures in detecting disease-related longitudinal change in Alzheimer's disease.
Winterlight partnered with Alzheimer Center Amsterdam on a funded study to characterize speech patterns in preclinical Alzheimer's disease and develop remote assessment tools.
With Genentech, Winterlight's research team presented findings at ADPD 2022 showing associations between speech characteristics and cerebral tau accumulation measured by tau PET imaging.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 1
primary sources listed
- Winterlightwinterlightlabs.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Winterlight do?
- Winterlight Labs analyzes short speech samples to detect and monitor cognitive impairment; acquired by Cambridge Cognition.
- Who are Winterlight's investors?
- Winterlight's investors include DG Daiwa Ventures, First Star Ventures, Hikma Ventures.